Man Group’s Galectin Therapeutics GALT Stock Holding History

Man Group’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,654	Closed	-$34.8K	–	2057
2024 Q3	$34.8K	Sell	12,654 -53,045	-81%	-$130K	﹤0.01%	1928
2024 Q2	$148K	Buy	+65,699	New	+$200K	﹤0.01%	1924

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Man Group's GALT Position: Q4 2024 in Review

Man Group sold out of Galectin Therapeutics (GALT) in Q4 2024, closing a stake of 12,654 shares — an estimated $34.8K sold.

Man Group first reported a position in GALT in Q2 2024 and held it in 2 quarters. The position peaked at $148K in Q2 2024. 94 funds tracked by Wall St. Rank hold GALT as of Q4 2024.

Man Group reported no remaining Galectin Therapeutics position as of Q4 2024 after selling out during the quarter.
Man Group sold 12,654 Galectin Therapeutics shares in Q4 2024, an estimated $34.8K.
Man Group first reported a position in Galectin Therapeutics in Q2 2024 and held it in 2 quarters.
Man Group's Galectin Therapeutics position peaked at $148K in Q2 2024.
94 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2024.

Based on Man Group's 13F filing for Q4 2024, filed 14 Feb 2025.